Literature DB >> 1499452

Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis.

S Itoh1, K Marutani, S Matsuo.   

Abstract

We studied the histological and ultrastructural changes in the liver and alterations in the liver test results before, during, and after treatment with human interferon-beta from five patients with hepatitis B e antigen-positive chronic active hepatitis. A daily dose of 3 x 10(6) to 6 x 10(6) units of interferon-beta was given intravenously for four weeks. The total index of periportal and portal inflammation, intralobular degeneration, and focal necrosis before treatment was decreased significantly six months after treatment (P less than 0.05). Ultrastructurally, the structure of endoplasmic reticulum was irregularly shaped or fragmentally decreased during treatment, but these disappeared six or 12 months after treatment. Glycogen particles diminished greatly during treatment. The alanine aminotransferase concentrations in these patients increased during treatment. Serum albumin and cholinesterase levels decreased significantly at the fourth week of treatment (P less than 0.01) and at the third day (P less than 0.01) to the second week (P less than 0.05) of treatment, respectively. These results suggest that interferon-beta injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499452     DOI: 10.1007/bf01296570

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy.

Authors:  W H Caselmann; J Eisenburg; P H Hofschneider; R Koshy
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

2.  Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes.

Authors:  M Saito; T Ebina; M Koi; T Yamaguchi; Y Kawade; N Ishida
Journal:  Cell Immunol       Date:  1982-03-15       Impact factor: 4.868

3.  Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.

Authors:  J H Hoofnagle; M Peters; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; C Hallahan; Y Park; C Meschievitz; E A Jones
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

4.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

Authors:  G H Scullard; R B Pollard; J L Smith; S L Sacks; P B Gregory; W S Robinson; T C Merigan
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

5.  Pilot study of recombinant human alpha-interferon for chronic type B hepatitis.

Authors:  J S Dooley; G L Davis; M Peters; J G Waggoner; Z Goodman; J H Hoofnagle
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

6.  In vitro augmentation of natural killing activity by OK-432.

Authors:  A Uchida; M Micksche
Journal:  Int J Immunopharmacol       Date:  1981

7.  The effect of alpha-interferon on the liver in a patient with hairy cell leukemia: light and electron microscopic studies.

Authors:  S Itoh; S Matsuo; K Shimoji; T Oda; I Sasaki; I Katayama
Journal:  Am J Gastroenterol       Date:  1989-08       Impact factor: 10.864

8.  Role of xanthine oxidase in the interferon-mediated depression of the hepatic cytochrome P-450 system in mice.

Authors:  G J Mannering; L B Deloria; V Abbott
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Depression of cytochrome P-450 and alterations of protein metabolism in mice treated with the interferon inducer polyriboinosinic acid X polyribocytidylic acid.

Authors:  N J Gooderham; G J Mannering
Journal:  Arch Biochem Biophys       Date:  1986-11-01       Impact factor: 4.013

View more
  2 in total

1.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Authors:  Gordon S Francis; Yves Grumser; Enrica Alteri; Alain Micaleff; Fanny O'Brien; Jonathan Alsop; Margaretha Stam Moraga; Neil Kaplowitz
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.